Clinical Trial: Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer

U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT07589543) titled 'Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer' on May 10.

Brief Summary: This study evaluates the safety, tolerability, and preliminary anti-tumor activity of EB-DUALNK, a dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy, in adults with recurrent or refractory epithelial ovarian cancer. Candidates for targeting include GD2, MUC1, PSMA, and mesothelin. After baseline biomarker assessment (tumor antigen expression), the program will select the most suitable dual-target pair for clinical testing. Participants will receive lymphodepleting chemotherapy followed by EB-DUALNK infusio...